Figure 1. The medication instruction sheet (MIS) for cytarabine and idarubicin induction therapy. This sheet was used to monitor for adverse events and verify the chemotherapy and supportive care medicine treatment schedule for patients with acute myeloid leukemia. The upper section indicates the treatment schedule for the chemotherapeutic agents and supportive care medicine, while the lower section represents predicted adverse events, their onset, and duration. A brief description for each adverse event is also included. AST: Aspartate aminotransferase; ALT: alanine aminotransferase.
